VEGF antagonist formulations suitable for intravitreal administration
US10400025B2 · kind B2 · utility
40Cited by
3References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 24, 2018 |
| Grant date | Sep 3, 2019 |
| Priority date | — |
| Expiry date | Jan 24, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.